News Releases Keyword Search Year None2022202120202019201820172016 Aug-02-2021 Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Aug-02-2021 Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference Jul-29-2021 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results Jul-01-2021 Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development Jun-01-2021 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) May-26-2021 Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference May-19-2021 Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021 May-19-2021 Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021 May-17-2021 Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer May-06-2021 Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
